Cancer patients who were treated with early or late line eribulin eribulin, breast cancer, survival, target trial emulation, propensity score
Conditions
Interventions
The early line group included those who received eribulin as first to third line therapy,The Late line group included those who received eribulin as fourth or more line therapy
Treatment,Treatment
Early line eribulin,Late line eribulin
Sponsors
None listed
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: women aged 18 years or older with histologically confirmed breast cancer and documented metastatic disease who received at least one cycle of eribulin during the study period.
Exclusion criteria
Exclusion criteria: Patients were excluded if baseline clinical data were incomplete or if eribulin was administered in the adjuvant or neoadjuvant setting.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival after receiving eribulin treatment hazard ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactChaichana Chantharakhit
Buddhasothorn hospital
Outcome results
None listed